Vanda Pharmaceuticals (VNDA) Cash from Operations Growth (1y) (2011 - 2026)
Vanda Pharmaceuticals (VNDA) Cash from Operations Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 7.14% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 356.73% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 74.39% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 3.23% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Vanda Pharmaceuticals | 310.98 Mn | 108.67 Mn | 48.56 Mn | -51.50% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -51.50% |
| Dec 31, 2025 | -1,518.99% |
| Sep 30, 2025 | -116.90% |
| Jun 30, 2025 | -120.15% |
| Mar 31, 2025 | -537.93% |
| Dec 31, 2024 | 51.31% |
| Sep 30, 2024 | -611.27% |
| Jun 30, 2024 | 47.59% |
| Mar 31, 2024 | -76.20% |
| Dec 31, 2023 | -139.63% |
| Sep 30, 2023 | -115.97% |
| Jun 30, 2023 | -332.54% |
| Mar 31, 2023 | 686.04% |
| Dec 31, 2022 | -64.61% |
| Sep 30, 2022 | 36.61% |
| Jun 30, 2022 | -70.11% |
| Mar 31, 2022 | -55.99% |
| Dec 31, 2021 | 37.85% |
| Sep 30, 2021 | 0.25% |
| Jun 30, 2021 | -20.78% |